BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 7,481 Shares of DexCom, Inc. (NASDAQ:DXCM)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lessened its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 10.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,354 shares of the medical device company's stock after selling 7,481 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in DexCom were worth $4,448,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom in the second quarter valued at about $25,000. Sachetta LLC increased its position in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after purchasing an additional 171 shares during the period. Riverview Trust Co raised its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares during the last quarter. DT Investment Partners LLC lifted its position in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after purchasing an additional 315 shares during the period. Finally, RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom in the 3rd quarter valued at $57,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is currently owned by insiders.

DexCom Price Performance

DXCM traded up $1.60 during trading on Tuesday, reaching $80.91. The stock had a trading volume of 3,551,800 shares, compared to its average volume of 3,917,172. The business has a 50-day moving average of $71.83 and a 200-day moving average of $86.83. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a market cap of $31.60 billion, a PE ratio of 48.45, a PEG ratio of 2.43 and a beta of 1.12.

Analyst Upgrades and Downgrades

DXCM has been the topic of several research analyst reports. Robert W. Baird upped their target price on DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, August 5th. Sanford C. Bernstein lifted their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, August 23rd. Leerink Partners reduced their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.